ERS Genomics and Sai Life Sciences sign CRISPR/Cas9 license agreement 

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announced that it has signed a non-exclusive license agreement with Sai Life Sciences , an integrated contract research, development, and manufacturing organization (CRDMO).

The agreement grants Sai Life Sciences access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio for use in research and product development. Through this license, Sai Life Sciences can integrate precision genome editing capabilities into its discovery and development platforms, strengthening its ability to support global pharmaceutical and biotechnology partners across small molecule programs.

Building on this access, Sai Life Sciences can deploy CRISPR/Cas9-enabled models and workflows to help clients validate targets, screen compounds and generate decision-relevant biological insights earlier in discovery, complementing its biology, DMPK and pharmacology platforms.

Maneesh Pingle, President, Discovery, Sai Life Sciences, said: “As the industry moves towards more complex biological questions and novel therapeutic approaches, we are continually expanding our scientific capabilities to stay ahead. The addition of CRISPR-Cas9 to our discovery platform is another step in that journey, strengthening our ability to support clients as they pursue the next generation of medicines. Our agreement with ERS Genomics gives us access to foundational CRISPR-Cas9 technology that will further strengthen these capabilities and expand the ways in which we can support our clients across discovery and development.”

John E. Milad, Chief Executive Officer, ERS Genomics, said: “We are delighted to welcome Sai Life Sciences as a licensee. Sai Life Sciences’ integrated discovery, development and manufacturing capabilities and its global base of innovator partners make it a strong addition to our growing network of CRISPR licensees. By securing access to our foundational CRISPR/Cas9 portfolio, Sai Life Sciences is well positioned to advance innovative research and development programmes with clarity and confidence.”

ERS Genomics provides access to the pioneering CRISPR/Cas9 intellectual property developed by Dr. Emmanuelle Charpentier and her collaborators. Through its streamlined licensing program, enables companies and institutions worldwide to access foundational patents covering the use of CRISPR/Cas9 technology across research and commercial applications.

The post ERS Genomics and Sai Life Sciences sign CRISPR/Cas9 license agreement  appeared first on Express Pharma.